Lilly is awaiting US and EU approvals to add Crohn’s disease to the IL-23 antagonist Omvoh (mirikizumab) and is already thinking about how to differentiate it from competing IL-23 drugs Skyrizi (risankizumab) and Tremfya (guselkumab), which have already shown benefits over Johnson’s established Crohn’s therapy Stelara (ustekinumab) in head-to-head studies.
Lilly Hopes To Differentiate Omvoh In Crohn’s With Histologic Data
The IL-23 antagonist Omvoh is under FDA/EMA review for Crohn’s disease; Lilly reported new Phase III data showing the drug is better than Stelara on multiple endpoints of histologic response.
